Drugs / C-CAR088
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04295018 | Oct 2019 → Sep 2021 | plasma cell myeloma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT04322292 | Sep 2019 → Sep 2022 | plasma cell myeloma | Institute of Hematology & Blood Diseases Hospital, China | Completed | No outcome recorded |
| Phase 1 | NCT03815383 | Apr 2019 → Jan 2021 | refractory plasma cell neoplasm | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 1 | NCT03751293 | Jan → Oct 2019 | refractory plasma cell neoplasm | Hebei Yanda Ludaopei Hospital | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05521802 | Nov 2022 → Jul 2024 overdue | plasma cell myeloma | Shanghai AbelZeta Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05632380 | Jul 2022 → Oct 2025 overdue | plasma cell myeloma | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C-CAR088 | “Autologous C-CAR088 administered by intravenous (IV) infusion” NCT05521802 ↗ |
| Modality | Cell therapy | “a novel second-generation humanized anti-BCMA CAR T-cell therapy” PMID 36100310 ↗ Sep 2022 |
| Route | Intravenous | “single infusion intravenously” NCT03751293 ↗ |